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Abstract: Herein, we present a one-step labeling procedure of N-succinimidyl-4-[18F]-fluorobenzoate
([18F]SFB) starting from spirocyclic iodonium ylide precursors. Precursor syntheses succeeded
via a simple one-pot, two-step synthesis sequence, in yields of approximately 25%. Subsequent
18F-nucleophilic aromatic labeling was performed, and radiochemical incorporations (RCCs) from
5–35% were observed. Purification could be carried out using HPLC and subsequent solid phase
extraction. Radiochemical purity (RCP) of >95% was determined. The total synthesis time,
including purification and formulation, was no longer than 60 min. In comparison to the established
3-step synthesis route of [18F]SFB, this one-step approach avoids formation of volatile radioactive
side-products and simplifies automatization.
Keywords: N-succinimidyl-4-[18F]fluorobenzoate; [18F]SFB; iodonium ylides; fluorine-18; PET
1. Introduction
N-succinimidyl-4-[18F]fluorobenzoate ([18F]SFB) is one of the most used prosthetic groups for
labeling of proteins and peptides. High conjugation yields and metabolic stability of the formed
construct facilitate its widespread use [1–7]. For example, [18F]SFB has been successfully applied in the
synthesis of inhibited factor VII [1], RGDs [4], or serum albumin [6]. Current synthesis approaches are
routinely based on a 3-step synthesis sequence starting with an 18F-aromatic nucleophilic substitution
(SNAr) of 4-(ethoxycarbonylphenyl)trimethylammonium triflate (1), followed by a hydrolysis step
of the corresponding ethyl ester (2) to the benzoic acid derivative [18F]3 ([18F]FBA) and finalized by
formation of [18F]SFB (Figure 1) [1–7]. In general, automation of 3-step synthesis procedures can be
challenging, and not all available synthesis modules support 3-step synthesis procedures. As such, the
synthesis of [18F]SFB cannot easily be implemented at all production sites. The 3-step synthesis of
[18F]SFB is further complicated since relatively high amounts of a volatile radioactive side-product,
probably [18F]FMe, are released [8]. This released side-product can limit the number of possible
syntheses repetitions before permitted release levels are reached. In this respect, one-step, direct
labeling conditions to synthesize [18F]SFB are highly desirable. Unfortunately, standard conditions,
which use relatively high amounts of base, result in hydrolysis of the active ester. As such, solely
[18F]3 is formed. Several attempts have been carried out to circumvent the aforementioned 3-step
procedure. This includes labeling of a (thiophen-2-yl)iodonium trifluoroacetate salt precursor [9],
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a TMP-iodonium-precursor [10], or boronic pinacol ester precursor [11]. None of the described
methods report an isolation step of the final product. Moreover, reports make use of aliquot labeling
conditions that can usually not easily be translated to one-step procedures with similar radiochemical
incorporations (RCCs) or radiochemical yields (RCYs) [12].
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Figure 1. Standard procedure vs. novel one-step approach; (A) 3-step synthesis of N-Succinimidyl-
4-[18F]Fluorobenzoate ([18F]SFB), (B) Novel synthesis approaches based on spirocyclic iodonium
ylide precursors.
Here, we report our efforts towards a one-step radiolabeling procedure to synthesize [18F]SFB.
We envisaged that spirocyclic iodonium ylide precursors bear the possibility to reach this goal.
Spirocyclic iodonium ylides are reported to result in high RCCs and in good RCYs. Furthermore, only
short reaction timeframes are necessary [12–14]. As such, we hypothesized that the nucleophilic attack
of the [18F]fluoride anion on the ylide leaving group could be faster than the competing hydrolysis of
the active ester. Subsequent quenching of the hydrolysis process shortly after the nucleophilic attack
would lead to the desired product, [18F]SFB. Moreover, the proposed strategy should prevent the
formation of volatile side-products.
2. Results and Discussion
In order to develop a one-pot, 18F-direct labeling strategy of [18F]SFB, four spirocyclic iodonium
ylide precursors 4a–d were synthesized according to literature procedures (Figure 2A) [15]. Precursors
4a–d were obtained in an overall chemical yield of approximately 25%. Aliquot labeling experiments
were carried out to investigate the capability of 4a–d to incorporate fluoride-18. As a starting point, we
ap lied 18F-labeling con itions that recently ave been shown to result in high RCCs within short
reaction times (Figure 2B, Supplementary Table S1) [12]. Quenc ing of the ydrolysis process was
conducted by adding 1.5% AcOH. During these ex eri e ts, the optimal time point in respect of
maximum fluorine-18 incorporation and minimizing [18F]3 formation was determined. An optimum
was reached after 5 min as longer reaction times lead to an increase in [18F]3 formation (Supplementary
Table S1). Precursor 4a and 4c resulted in a maximum RCC of approximately 35%, whereas 4b and
4d only resulted in RCCs around 5% (Table 1). These initial results encouraged us to investigate the
reliability of the reaction. Precursor 4a was selected as a model compound for this purpose. A high
variability was detected that spanned from 1–33% RCC with a mean of 17.8 ± 17% (n = 26). We believe
that this variability is due to different basicity values stemming from slightly different water content and
base concentration within the final reaction mixture. Absolute water content and base concentration
are very difficult to control within standard labeling procedures and can vary. In turns, sensitive
reactions can be strongly influenced by these concentration differences. In our case, we believe that
these differences could lead to an accelerated hydrolysis step and, as such, higher amounts of [18F]3 are
formed. To minimize this, we investigated the influence of various bases, such as tetraethylammonium
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bicarbonate (TEAB), KHCO3, or Cs2CO3. Only trace amounts of [18F]SFB could be detected using these
bases (Supplementary Table S2). The addition of (2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO),
which is reported to increase the RCC of this type of reactions [12], and the change of phase transfer
catalyst did not improve the yield, either. Furthermore, the use of N,N-dimethylformamide (DMF)
turned out to be essential for the reaction (Supplementary Table S2). In an attempt to reduce the water
content within the final reaction mixture, as well as to accelerate 18F-incorporation, microwave heating
was applied; unfortunately, it was unsuccessful. Consequently, we did not succeed in improving the
variability of the reaction.
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Figure 2. (A) Four different precursors were synthesized to find the best precursor for one-step
formation of [18F]SFB. (B) General labeling scheme.
Table 1. One-step labeling procedure to synthesize [18F]SFB.
Precursor RCC [%] RCY [%]
4a 1–33 n = 26 2–15 n = 7
4b 5 n = 3 - -
4c 8–35 n = 2 1–2 n = 2
4d 6 n = 2 - -
RCC = radiochemical conversion; RCY = radiochemical yield.
Despite these failed attempts, we were interested in upscaling the reaction. Precursors 4a and
4c were selected for this endeavor. A non-decay corrected RCY of 1–15% at the end of synthesis
with a low molar activity of 2 GBq/µmol and a radiochemical purity (RCP) of >95% could be
reached (Figure 3A). The total reaction time was below 60 min, including HPLC purification and final
formulation. No release of any radioactive side-product was observed. Figure 3 shows a typical HPLC
chromatogram of [18F]SFB after purification and formulation. The displayed sample was spiked with
reference compound for identification purposes. Finally, we tested if [18F]SFB can indeed be used for
labeling purposes. A 50 kDa protein (Active site-inhibited FVII (FVIIai) was successfully labeled with
[18F]SFB. The product, [18F]FVIIai, was isolated in a satisfying RCY of 11% compared to the starting
activity amount of [18F]SFB (Figure 3B).
In comparison to commonly used 3-step procedures, the new method resulted in relatively low,
but for preclinical application, acceptable non-decay corrected RCY (2–15%). RCYs showed a high
variability. Average RCY was 4%, lowest 2%. Comparable RCP and synthesis time were achieved
with the new method. Table 2 compares the results of this work towards published 3-step labeling
procedures. Finally, labeling of FVIIai resulted in slightly lower RCY compared to the use of [18F]SFB
produced in a 3-step labeling approach (11% vs. 25 ± 9%) [1].
Molecules 2019, 24, 3436 4 of 7
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Figure 3. (A) [18F]SFB synthesized in 1-step after HPLC purification. Reference compound is co-injected
for chemical identification purposes. (B) [18F]SFB reacted with FVIIai and purified with a PD10 column.
Table 2. Comparison of published [18F]SFB syntheses.
Method RCY (d.c.) [%] RCY (n.d.c.) [%] RCP [%] Synthesis Time [min]
This work 3–22 2–15 (average 4) >95 <60
Vaidyanathan [3] 30–35 18–21 n.d. 80
Thonon et al. [4] 42 ± 3 29 ± 2 98 57
Li et al. [5] 80 ± 3 60 ± 2 97 45
Ackermann et al. [7] 75–85 51–59 95–98 58
n.d. = not determined; RCY = radiochemical yield; RCP = radiochemical purity; d.c. = decay corrected;
n.d.c. = non-decay-corrected
3. Materials and Methods
Solvents and reagents were purchased from Sigma Aldrich (Darmstadt, Germany) or Thermo
Fisher Scientific (Waltham, MA, USA). Reference compound SFB was purchased from ABX advanced
biochemical compounds (Radberg, Germany). 400 MHz 1H-NMR and diffusion-ordered spectra were
recorded on a Bruker Avance III HD 400 spectrometer (Billerica, MA, USA) at room temperature.
Chemical shifts are reported in ppm and were referenced to the solvent residual signal. The analysis of
the 1H-NMR spectra was performed using the software MestReNova v12.0.0 (Mestrelab Research S.L.,
Santiago de Compostela, Spain)). Thin-layer chromatography (TLC) was carried out using normal
phase plates (silica gel 60 coated with fluorescent indicator F254s) from Merck (Darmstadt, Germany).
The fraction of radioactivity on the TLC-plates was measured with an instant imager from Packard
InstantImager (Detroit, MI, USA) and analyzed by Optiquant software v1.2 (PerkinElmer, Waltham,
MA, USA). Analytical HPLC was performed on a Dionex (Sunnyvale, CA, USA) system connected to a
P680A pump, a UVD 170U detector, and a radiodetector from Scansys Laboratorieteknik (Vanløse,
Denmark). HPLC control and spectra processing were done with Chromeleon 6.8 software (Waltham,
MA, USA).
3.1. General Procedure to Formation of Spirocyclic SFB Precursors
2,5-dioxopyrrolidin-1-yl 4-iodobenzoate (120 mg, 0.35 mmol) was dissolved in acetonitrile (ACN)
(0.2 mL) and added to a solution of Selectfluor (140 mg, 1.5 eq.) and Me3SiOAc (0.21 mL, 2.7 eq.) in
ACN (1.5 mL). The vial with the solution was capped and stirred for 36 h at 75 ◦C. This mixture was
then cooled to RT. The desired acid (1 eq) was dissolved in a solution of 10% aq. Na2CO3 (0.2 mL) and
ACN (0.1 mL), added to the former mixture, and stirred for 1 h. Afterwards, 5 mL water was added,
and the resulting mixtures extracted with 3 ×DCM (15 mL). The product was purified via flash column
chromatography, as specified.
Molecules 2019, 24, 3436 5 of 7
3.2. 2,5-dioxopyrrolidin-1-yl 4-((7,9-dioxo-6,10-dioxaspiro[4.5]decan-8-ylidene)- λ3-iodaneyl)benzoate (4a)
Produced via the general procedure, using 6,10-dioxaspiro[4.5]decane-7,9-dione (60 mg, 1 eq) as
the corresponding acid, the product was purified via flash column chromatography starting from 100%
n-Hep to 50% DCM in n-Hep, followed by 10:45:45 EtOH:n-Hep:DCM to give 2,5-dioxopyrrolidin-1-yl
4-((7,9-dioxo-6,10-dioxaspiro[4.5]decan-8-ylidene)-λ3-iodaneyl)benzoate (4a) 45 mg (25%). Rf 0.65 (10%
MeOH in DCM). The compound was stored at −18 ◦C. 1H-NMR (400 MHz, DMSO): δ 8.14 (dd, 2H)
8.06 (dd, 2H), 2.90 (s, 4H), 2.01 (m, 4H), 1.70 (m, 4H); 13C-NMR (101 MHz, DMSO): δ 170.1, 163.5, 161.1,
133.1, 132.0, 126.3, 123.7, 112.3, 58.9, 36.8, 25.5, 22.8.
3.3. 2,5-dioxopyrrolidin-1-yl 4-(((5r,7r)-4′,6′-dioxospiro[adamantane-2,2′-[1,3]dioxan]-5′-ylidene)-
λ3-iodaneyl)benzoate (4b)
Produced via the general procedure, using (5r,7r)-spiro[adamantane-2,2′-[1,3]dioxane]-4′,6′-dione
(138 mg, 1 eq) as the corresponding acid, the product was purified via flash column
chromatography starting from 100% n-Hep to 50% DCM in n-Hep, followed by 10:45:45 EtOH:n-
Hep:DCM to give 2,5-dioxopyrrolidin-1-yl 4-(((5r,7r)-4′,6′-dioxospiro[adamantane-2,2′-[1,3]dioxan]-
5′-ylidene)-λ3-iodaneyl)benzoate (4b) 25 mg (7%). Rf 0.44 (10% MeOH in DCM). The compound was
stored at −18 ◦C. 1H-NMR (400 MHz, CDCl3): δ 8.16 (dd, 2H) 8.02 (dd, 2H), 2.90 (s, 4H), 2.44 (s, 2H),
2.17 (m, 4H)1.87 (s, 2H), 1.73 (m, 5H); 13C-NMR (101 MHz, DMSO): δ 170.6, 163.0, 161.6, 139.1, 138.1,
133.5, 132.5, 126.8, 124.1, 105.8, 58.2, 37.0, 35.3, 33.7, 26.4, 26.0.
3.4. 2,5-dioxopyrrolidin-1-yl 4-((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)-λ3-iodaneyl)benzoate (4c)
Produced via the general procedure, using 2,2-dimethyl-1,3-dioxane-4,6-dione (41 mg, 1 eq) as the
corresponding acid, the product was purified via flash column chromatography starting from 100%
n-Hep to 50% DCM in n-Hep, followed by 10:45:45 EtOH:n-Hep:DCM to give 2,5-dioxopyrrolidin-1-yl
4-((2,2-dimethyl-4,6-dioxo-1,3-dioxan-5-ylidene)- λ3-iodaneyl)benzoate (4c) 85 mg (62%). Rf 0.51 (10%
MeOH in DCM). The compound was stored at −18 ◦C. 1H-NMR (400 MHz, DMSO): δ 8.14 (dd, 2H)
8.04 (dd, 2H), 2.90 (s, 4H), 1.59 (s, 6H); 13C-NMR (101 MHz, DMSO): δ 170.1, 162.9, 161.1, 133.3, 132.0,
126.3, 123.8, 102.9, 58.2, 25.6, 25.5.
3.5. 2,5-dioxopyrrolidin-1-yl 4-((1,3-dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)-
λ3-iodaneyl)benzoate (4d)
Produced via the general procedure, using 1,3-dimethylpyrimidine-2,4,6(1H,3H,5H)-trione (45 mg,
1 eq) as the corresponding acid, the product was purified via flash column chromatography
starting from 100% n-Hep to 50% DCM in n-Hep, followed by 10:45:45 EtOH:n-Hep:DCM
to give 2,5-dioxopyrrolidin-1-yl 4-((1,3-dimethyl-2,4,6-trioxotetrahydropyrimidin-5(2H)-ylidene)-
λ3-iodaneyl)benzoate (4d) 50 mg (35%). Rf 0.50 (10% MeOH in DCM). The compound was stored at
−18 ◦C. 1H-NMR (400 MHz, DMSO): δ 8.10 (dd, 2H) 8.06 (dd, 2H), 3.18 (s, 6H), 2.89 (s, 4H); 13C-NMR
(101 MHz, DMSO): δ 170.1, 161.1, 160.9, 152.6, 133.0, 132.0, 126.2, 123.5, 70.1, 28.5, 25.5.
3.6. Labeling of [18F]SFB – Automatization
[18F]Fluoride was produced via a (p,n)-reaction on a CTI Siemens cyclotron by irradiating [18O]H2O
with 11 MeV protons. An anion exchange resin (Sep-Pak Light Waters Accell Plus QMA cartridge
(Milford, MA, USA)) was washed with EtOH (20 mL), 0.5 M K2CO3 (aq) (10 mL) and water (20 mL) and
dried with air. Then, the aqueous [18F]fluoride solution was passed through this exchange resin and
the resin eluted with a Kryptofix222 (K222: 4,7,13,16,21,24-hexaoxa-1,10diazabicyclo[8.8.8]hexa-cosane)
10 mg, 1.2 mg K2CO3 in 0.1 mL H2O, and 0.6 mL MeOH). The resulting mixture was then gently
concentrated to dryness at 90 ◦C by azeotropic drying with 2 × ACN (0.6 mL), under a nitrogen stream
for 20 min, to give no-carrier-added K[18F]F–K222 complex as a white semi-solid residue.
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Precursor 4a (5 mg) was dissolved in 0.3 mL DMF. This mixture was added to the dried [18F]FK/K222
complex and heated to 135 ◦C for 4 min. Then this mixture was transferred to 2 mL of 1.5% AcOH (aq.)
and, afterwards, purified via semi-preparative HPLC (LUNA (phenomenex) 250 × 10 mm, 5 µm, 50:50
ACN:H2O (0.1% TFA) 3 mL/min, RT: 700 sec [18F]SFB). The fraction containing [18F]SFB was collected
into a vial containing 30 mL water. The product was first trapped on the SepPak plus cartridge and,
afterwards, eluted with ACN (2 mL) and, finally, evaporated to dryness under a stream of helium.
Typically, 2–15% RCY was obtained (not decay corrected) in a synthesis time of 1 h, including drying
of fluorine-18.
3.7. Labeling of [18F]FVIIai
Active site inhibited factor VII (1.2 mg in 500-µL HEPES buffer, pH 7.8) was added to purified and
dried [18F]SFB and stirred gently for 30 min at room temperature. The final purification of [18F]FVIIai
was conducted on a PD-10 desalting column eluting with phosphate buffered saline collecting fractions
of 0.5 mL. Fractions 4 to 8 contained [18F]FVIIai corresponding to 11% incorporation of [18F]SFB.
4. Conclusions
A one-step labeling procedure for [18F]SFB was developed. RCYs with a maximum RCY of 15%
could be reached in less than 1 h. The product was radiochemical pure. No release of radioactive
side-product was observed. Unfortunately, large variations in the yield were observed. This is due to
hydrolysis of the active ester into [18F]FBA ([18F]3). Future efforts will be directed to minimize the
hydrolysis step and increase the reliability of the reaction.
Supplementary Materials: Analytical HPLC and NMR data, additional experimental data including analytical
HPLC conditions and reaction optimization attempts are reported.
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